Fortress Biotech Stock Quote FBIO - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.79

Bid

1.76

Ask

1.80

Volume

115,102

1.76 Day's Range 1.80

1.24 52 Week Range 11.9985

Market Cap

32.527M

Previous Close

1.81

Open

1.79

Last Trade

1.8

Last Trade Time

Financial Volume

$ 205,683

VWAP

1.787

Average Volume (3m)

295,368

Shares Outstanding

18,376,750

Dividend Yield

PE Ratio

-0.47

Earnings Per Share (EPS)

-3.74

Revenue

84.51M

Net Profit

-68.67M

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.fortressbiotech.com

Headquarters

Dover, Delaware, USA

Founded

1970

Fortress Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FBIO. The last closing price for Fortress Biotech was $1.81. Over the last year, Fortress Biotech shares have traded in a share price range of $ 1.24 to $ 11.9985.

Fortress Biotech currently has 18,376,750 shares outstanding. The market capitalization of Fortress Biotech is $32.53 million. Fortress Biotech has a price to earnings ratio (PE ratio) of -0.47.

Avenue Therapeutics Announces Reverse Stock Split

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and...

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application...

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the...

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and...

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings...

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily...

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	1.79	1.88	1.7	242227	1.78519439	CS
4	-0.17	-8.67346938776	1.96	2.17	1.64	247831	1.88871981	CS
12	-0.22	-10.9452736318	2.01	2.615	1.63	295368	1.93376851	CS
26	0	0	1.79	4.43	1.24	559617	2.28767759	CS
52	-8.71	-82.9523809524	10.5	11.9985	1.24	561805	5.08321714	CS
156	-63.01	-97.237654321	64.8	71.85	1.24	535662	21.05259009	CS
260	-25.21	-93.3703703704	27	91.5	1.24	650206	35.68130884	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.43 (182.34%)	220.51M
AIREreAlpha Tech Corporation	$ 1.14 (88.74%)	35.42M
BOFBranchOut Food Inc	$ 2.0144 (72.17%)	107.44M
LICNLichen China Limited	$ 0.94 (67.86%)	15.08M
AMSTAmesite Inc	$ 3.31 (65.50%)	70.3M
NCINeo Concept International Group Holdings Ltd	$ 2.33 (-75.47%)	8.33M
GCTKGlucoTrack Inc	$ 0.466 (-38.68%)	1.7M
ISUNiSun Inc	$ 0.0922 (-38.12%)	9.79M
VAXXVaxxinity Inc	$ 0.1326 (-33.70%)	4.95M
EVOEvotec SE	$ 5.2199 (-31.77%)	1.55M
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.43 (182.34%)	220.51M
TSLATesla Inc	$ 162.13 (12.06%)	181.24M
SQQQProShares UltraPro Short QQQ	$ 11.81 (-0.84%)	148.21M
BOFBranchOut Food Inc	$ 2.0144 (72.17%)	107.44M
NKLANikola Corporation	$ 0.6206 (-2.31%)	80.82M